Stay Connected. Be the first to hear about upcoming initiatives.
We respect your privacy and take protecting it seriously. Learn more in our Privacy Policy.
Headquarters
25 Massachusetts Avenue NWSuite 730
Washington, D.C. 20001
Phone: 202.864.5920
Fax: 202.864.5930
San Francisco Office
214 Grant AvenueSuite 325
San Francisco, CA 94108
New Legislation Will Accelerate American Innovation and Competitiveness
WASHINGTON, DC – The National Venture Capital Association (NVCA), TechNet, and the Center for American Entrepreneurship (CAE) are excited to see the introduction of several tax policy measures that will increase investment in frontier technologies and new tools to better prepare the country for future pandemics and other public health crises.
U.S. Venture Ecosystem Normalizes After Record Year in 2021
VC Exit Activity Slows in Q1 While Fundraising Totals Stay Strong SEATTLE – Venture capital (VC) dealmaking activity adjusted to a new normal in the first quarter of 2022 after a record-breaking 2021 according to the Q1 2022 PitchBook-NVCA Venture Monitor, the authoritative quarterly report jointly produced by PitchBook and the National Venture Capital Association […]
New JOBS Act 4.0 Boosts the Next Generation of High Growth American Companies
WASHINGTON, DC – NVCA strongly supports provisions in the newly announced JOBS Act 4.0 package that facilitate capital formation and make the public markets more attractive for innovative young companies.
DEAL Act Paves Way for More Startups Enhancing U.S. Economy
WASHINGTON, DC – NVCA is excited to see the reintroduction of the Developing and Empowering our Aspiring Leaders (DEAL) Act by Senator Mike Rounds (R-SD), a longtime legislative priority that will help improve returns and capital formation in the initial stages of the startup ecosystem.
Startups in 400+ Congressional Districts Received VC Funding Last Year; Globally, U.S. Accounted for Less Than 50% of VC Dollars and 40% of Deal Count
WASHINGTON, DC – More than 14,400 U.S. venture-backed companies across 251 metro areas and 414 Congressional Districts raised funding in 2021, a new annual record for the number of companies raising venture capital (VC). The pace of investment averaged out to about 40 companies across the country raising VC funding each day, according to the National Venture Capital […]
Employment at U.S. VC-backed Companies Grew 960% from 1990 to 2020, 8x Compared to Non-VC-backed Companies
WASHINGTON, DC — Employment at venture capital (VC)-backed companies dramatically outpace employment at non-VC-backed companies, and -backed companies create jobs that are broadly dispersed across the nation, according to a new report from the National Venture Capital Association, Venture Forward, and the University of North Carolina Kenan Institute of Private Enterprise.
NVCA Statement on Startup Visa Passage
Washington DC– NVCA President and CEO Bobby Franklin following House passage of the America Competes Act which included a Startup Visa said:
U.S. Venture Capital Activity Soars to New Highs in 2021 as Deal Value Exceeds $300 Billion and Fundraising Tops $100 Billion
SEATTLE – Venture capital dealmaking, exit and fundraising values all broke records in 2021 by stunning amounts, according to the PitchBook-NVCA Venture Monitor, the authoritative quarterly report produced by PitchBook and the National Venture Capital Association with support from Insperity.
Senate Antitrust Bill Hurts Innovation, Growth and Creation of New Innovative American Companies
Washington, DC – NVCA President and CEO Bobby Franklin says threatening American made innovation is the wrong way to address Big Tech. The newly introduced Platform Competition and Opportunity Act from Senators Amy Klobuchar (D-MN) and Tom Cotton (R-AK) would bar acquisitions of many venture-backed companies and therefore be a major disincentive to entrepreneurship. “Startups […]
Expedited Coverage for Medical Technologies Will Drive Healthcare Innovation
WASHINGTON, DC – The National Venture Capital Association strongly urges the Centers for Medicare and Medicaid Services (CMS) to expedite coverage for innovative medical technologies by prioritizing reforms to the reimbursement process. The existing reimbursement policy and the uncertainty that follows approval of new medical products has led to the decline in medical device investment […]